Psychologic intervention improves survival for breast cancer patients: A randomized clinical trial

Cancer

Volumn 113, Issue 12, 2008, Pages 3450-3458

  Andersen, Barbara L ^a,b   Yang, Hae Chung ^a   Farrar, William B ^b,c   Golden Kreutz, Deanna M ^c   Emery, Charles F ^a   Thornton, Lisa M ^a   Young, Donn C ^b   Carson III, William E ^b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Biobehavioral; Breast; Cancer; Intervention; Psychologic; Recurrence; Survival

Indexed keywords

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH BEHAVIOR; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MOOD; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STRESS; SURVIVAL;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERVIEW, PSYCHOLOGICAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; PSYCHOTHERAPY, GROUP; STRESS, PSYCHOLOGICAL;

EID: 57649123246     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23969     Document Type: Article

References (52)

1. Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psychological factors contribute to cancer incidence and survival? Nat Clin Pract Oncol. 2008;5:466-475.
2. Dhabhar FS, McEwen BS. Bi-directional effects of stress on immune function: Possible explanations for salubrious as well as harmful effects. In: Ader R, ed. Psychoneuroimmunology. New York, NY: Elsevier; 2007:723-760.
3. Antoni MH, Lutgendorf SK, Cole SW, et al. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer. 2006;6:240-248.
4. Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008;26:971-982.
5. Andersen BL, Kiecolt-Glaser JK, Glaser R. A biobehavioral model of cancer stress and disease course. Am Psychol. 1994;49:389-404.
6. Andersen BL, Farrar WB, Golden-Kreutz DM, et al. Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J Clin Oncol. 2004;22:3570-3580.
7. Fleming ID, Cooper JS, Murphy GP, Sullivan BO, Sobin LH, Yarbro JW, eds. AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven; 1997.
8. White SJ, Freedman LS. Allocation of patients to treatment group in a controlled clinical trial. Br J Cancer. 1978;37:849-857.
9. Scott NW, McPherson GC, Ramsay CR, Campbell MK. The method of minimization for allocation to clinical trials: a review. Control Clin Trials. 2002;23:662-674.
10. Andersen BL, Farrar WB, Golden-Kreutz D, et al. Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behav Immun. 2007;21:953-961.
11. Andersen BL, Shelby RA, Golden-Kreutz DM. Results from an RCT of a psychological intervention for patients with cancer: I. Mechanisms of change. J Consult Clin Psychol. 2007;75:927-938.
12. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med. 1979;41:209-218.
13. Kohout FJ, Berkman LF, Evans DA, Cornoni-Huntley J. Two shorter forms of the CES-D Depression Symptoms Index. J Aging Health. 1993;5:179-193.
14. Cox DR. Regression models and life-tables. J R Stat Soc. 1972;34:187-220.
15. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949:199-205.
16. McNair DM, Lorr M, Droppleman LF. EITS Manual for the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service; 1971.
17. Confer PD. The James Cancer Registry. Columbus, OH: The Ohio State University Comprehensive Cancer Center; 2008.
18. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst. 2004;96:1311-1321.
19. Kissane DW, Bloch S, Smith GC, et al. Cognitive-existential group psychotherapy for women with primary breast cancer: a randomised controlled trial. Psychooncology. 2003;12:532-546.
20. Kissane DW, Grabsch B, Clarke DM, et al. Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial. Psychooncology. 2007;16:277.
21. Goodwin PJ, Leszcz M, Ennis M. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med. 2001;345:1719-1726.
22. Spiegel D, Butler LD, Giese-Davis J, et al. Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial. Cancer. 2007;110:1130-1138.
23. Vandewalle B, Revillion F, Lefebvre J. Functional beta-adrenergic receptors in breast cancer cells. J Cancer Res Clin Oncol. 1990;116:303-306.
24. Sood AK, Bhatty R, Kamat AA, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res. 2006;12:369-375.
25. Stefanski V, Ben-Eliyahu S. Social confrontation and tumor metastasis in rats: defeat and beta-adrenergic mechanisms. Physiol Behav. 1996;60:277-282.
26. Masur K, Niggemann B, Zanker KS, Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res. 2001;61:2866-2869.
27. 22-adrenergic receptor. J Cell Biol. 2003;160:487-493.
28. Thaker PH, Lutgendorf SK, Sood AK. The neuroendocrine impact of chronic stress on cancer. Cell Cycle. 2007;6:430-433.
29. Raison CL, Miller AH. Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychol. 2003;54:283-294.
30. Badino GR, Novelli A, Girardi C, Di Carlo F. Evidence for functional β-adrenoceptor subtypes in CG-5 breast cancer cells. Pharmacol Res. 1996;33:255-260.
31. Kronfol Z, Nair M, Zhang Q, Hil EE, Brown MB. Circadian immune measures in healthy volunteers: relationship to hypothalamic-pituitary-adrenal axis hormones and sympathetic neurotransmitters. Psychosom Med. 1997;59:42-50.
32. Rich T, Innominato PF, Boerner J, et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res. 2005;11:1757-1764.
33. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92:994-1000.
34. Mormont MC, Waterhouse J, Bleuzen P, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2000;6:3038-3045.
35. Ben-Eliyahu S, Yirmiya R, Liebeskind JC, Taylor AN, Gale RP. Stress increases metastatic spread of a mammary tumor in rats: evidence for mediation by the immune system. Brain Behav Immun. 1991;5:193-205.
36. Kalinichenko VV, Mokyr MB, Graf LH Jr, Cohen RL, Chambers DA. Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a beta-adrenergic receptor mechanism and decreased TNF-alpha gene expression. J Immunol. 1999;163:2492-2499.
37. Andersen BL, Farrar WB, Golden-Kreutz D, et al. Stress and immune responses after surgical treatment for regional breast cancer. J Natl Cancer Inst. 1998;90:30-36.
38. Kim S, Keku TO, Martin C, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res. 2008;68:323-328.
39. Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and anti-inflammatory cytokines, and autoimmunity. Ann N Y Acad Sci. 2002;966:290-303.
40. Merritt WM, Lin YG, Spannuth WA, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008;100:359-372.
41. Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12:939-944.
42. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 2007;67:10019-10026.
43. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res. 2004;64:1757-1764.
44. Thornton LM, Andersen BL, Carson WE III. Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis. Cancer Immunol Immunother. 2008;57:1471-1481.
45. Morrow GR, Andrews PL, Hickok JT, Roscoe JA, Matteson S. Fatigue associated with cancer and its treatment. Support Care Cancer. 2002;10:389-398.
46. Anisman H, Hayley S, Turrin N, Merali Z. Cytokines as a stressor: implications for depressive illness. Int J Neuropsychopharmacol. 2002;5:357-373.
47. Ruka W, Rutkowski P, Kaminska J, Rysinska A, Steffen J. Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance. Ann Oncol. 2001;12:1423-1432.
48. Redd WH, Montgomery GH, DuHamel KN. Behavioral intervention for cancer treatment side effects. J Natl Cancer Inst. 2001;93:810-823.
49. Sheard T, Maguire P. The effect of psychological interventions on anxiety and depression in cancer patients: results of 2 meta-analyses. Br J Cancer. 1999;80:1770-1780.
50. Adler NE, Page AEK. Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs. Washington, DC: The National Academies Press; 2008.
51. Beslija SEA, Bonneterre J, Burstein HJ, et al. For the Central European Cooperative Group. Consensus on the medical treatment of metastatic breast cancer. Breast Cancer Res Treat. 2003;81:1-7.
52. Hewitt M, Herdman R, Holland J, eds. The effectiveness of psychosocial interventions for women with breast cancer. In: Meeting Psychosocial Needs of Women with Breast Cancer. Washington, DC: The National Academies Press; 2004:95-132.